|
CA2372316A1
|
|
The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
|
|
CA2312266A1
|
|
The use of hcarg, a novel calcium-regulated gene coding for a nuclear protein, for regulating cell proliferation
|
|
CA2302627A1
|
|
Constructs comprising the enac promoter sequence and a reporter gene for screening pharmaceuticals
|
|
EP1146885A1
|
|
Pre-conditioning against cell death
|
|
CA2337083A1
|
|
Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof
|
|
EP1100533A2
|
|
Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof
|
|
CA2256123A1
|
|
A novel hypertension related calcium regulated gene (hcarg)
|
|
CA2276013A1
|
|
The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
|
|
AU9731898A
|
|
The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
|
|
CA2303069A1
|
|
Treatment of stress and preconditioning against stress
|
